Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944839 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
A Phase 3 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 619
- Enrollment target
NCT01944839: Clinical Trial Phase 3 study, sponsored by Ophthotech Corporation.
NCT01944839 is a Phase 3 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 619 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01944839, a Phase 3 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 619 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Interventions
- DRUG ranibizumab
- DRUG E10030
- DRUG E10030 sham intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01944839
The ClinicalTrials.gov registry entry for NCT01944839 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 619 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT01944839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01944839 about?
NCT01944839 is a clinical study titled "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy". The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT01944839?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2013-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01944839?
The interventions under investigation include: ranibizumab (DRUG), E10030 (DRUG), E10030 sham intravitreal injection (DRUG).
Who is sponsoring clinical trial NCT01944839?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.